JP2007515402A - 哺乳動物および鳥類の体脂肪および体重の減少方法 - Google Patents
哺乳動物および鳥類の体脂肪および体重の減少方法 Download PDFInfo
- Publication number
- JP2007515402A JP2007515402A JP2006541282A JP2006541282A JP2007515402A JP 2007515402 A JP2007515402 A JP 2007515402A JP 2006541282 A JP2006541282 A JP 2006541282A JP 2006541282 A JP2006541282 A JP 2006541282A JP 2007515402 A JP2007515402 A JP 2007515402A
- Authority
- JP
- Japan
- Prior art keywords
- salbutamol
- isomer
- mammal
- beta
- birds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 210000000577 adipose tissue Anatomy 0.000 title claims abstract description 36
- 241000124008 Mammalia Species 0.000 title claims abstract description 33
- 229960002052 salbutamol Drugs 0.000 claims abstract description 68
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims abstract description 51
- 230000037396 body weight Effects 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 230000000694 effects Effects 0.000 claims description 46
- 241000287828 Gallus gallus Species 0.000 claims description 28
- 241000271566 Aves Species 0.000 claims description 24
- 235000013330 chicken meat Nutrition 0.000 claims description 18
- 241000282412 Homo Species 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 10
- 239000000614 adrenergic beta-2 receptor agonist Substances 0.000 claims description 9
- 229940044601 receptor agonist Drugs 0.000 claims description 8
- 239000000018 receptor agonist Substances 0.000 claims description 8
- 229940124627 adrenergic β2 receptor agonist Drugs 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 4
- 241000282472 Canis lupus familiaris Species 0.000 claims description 4
- 241000282994 Cervidae Species 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- 241000286209 Phasianidae Species 0.000 claims description 4
- 241000282887 Suidae Species 0.000 claims description 4
- 241000272517 Anseriformes Species 0.000 claims description 3
- 241000283086 Equidae Species 0.000 claims description 3
- 241000282326 Felis catus Species 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 230000001800 adrenalinergic effect Effects 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims 2
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 50
- 241001465754 Metazoa Species 0.000 description 48
- 239000003814 drug Substances 0.000 description 41
- 229940079593 drug Drugs 0.000 description 20
- 235000005911 diet Nutrition 0.000 description 18
- 230000037213 diet Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 238000011282 treatment Methods 0.000 description 15
- 229940124748 beta 2 agonist Drugs 0.000 description 11
- 229960001117 clenbuterol Drugs 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 244000144977 poultry Species 0.000 description 10
- 235000013594 poultry meat Nutrition 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 239000000808 adrenergic beta-agonist Substances 0.000 description 9
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 9
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 9
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 244000144972 livestock Species 0.000 description 8
- 230000004580 weight loss Effects 0.000 description 8
- 229960002848 formoterol Drugs 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 230000002366 lipolytic effect Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- -1 4-amino-α-[(tert-butylaminomethyl)]-3,5-dichlorobenzyl Chemical group 0.000 description 5
- 235000020940 control diet Nutrition 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 229960004017 salmeterol Drugs 0.000 description 5
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 4
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 4
- 210000000579 abdominal fat Anatomy 0.000 description 4
- 230000007059 acute toxicity Effects 0.000 description 4
- 231100000403 acute toxicity Toxicity 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000011436 cob Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 229940074095 ractopamine Drugs 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 235000019750 Crude protein Nutrition 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940125388 beta agonist Drugs 0.000 description 3
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 description 3
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- YJQZYXCXBBCEAQ-UHFFFAOYSA-N ractopamine Chemical compound C=1C=C(O)C=CC=1C(O)CNC(C)CCC1=CC=C(O)C=C1 YJQZYXCXBBCEAQ-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011076 safety test Methods 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960000195 terbutaline Drugs 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000001796 Melanocortin 4 receptors Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 235000019755 Starter Diet Nutrition 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 2
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000000022 bacteriostatic agent Substances 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- 229960001317 isoprenaline Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229960002288 procaterol Drugs 0.000 description 2
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000006054 starter diet Substances 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 235000021195 test diet Nutrition 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NUBLQEKABJXICM-FQEVSTJZSA-N (1r)-1-(4-amino-3,5-dichlorophenyl)-2-[6-(2-pyridin-2-ylethoxy)hexylamino]ethanol Chemical compound C1=C(Cl)C(N)=C(Cl)C=C1[C@@H](O)CNCCCCCCOCCC1=CC=CC=N1 NUBLQEKABJXICM-FQEVSTJZSA-N 0.000 description 1
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 1
- BUXRLJCGHZZYNE-UHFFFAOYSA-N 2-amino-5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzonitrile Chemical compound CC(C)NCC(O)C1=CC=C(N)C(C#N)=C1 BUXRLJCGHZZYNE-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- NKKPVWPMPWLEMY-UHFFFAOYSA-N 4-[2-[4-(benzimidazol-1-yl)butan-2-ylamino]-1-hydroxyethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC(C(O)CNC(C)CCN2C3=CC=CC=C3N=C2)=C1 NKKPVWPMPWLEMY-UHFFFAOYSA-N 0.000 description 1
- BMMHZTIQZODVHZ-UHFFFAOYSA-N 4-[2-[[2-[3-amino-5-(hydroxymethyl)phenyl]-2-hydroxyethyl]amino]propyl]phenol Chemical compound C=1C(N)=CC(CO)=CC=1C(O)CNC(C)CC1=CC=C(O)C=C1 BMMHZTIQZODVHZ-UHFFFAOYSA-N 0.000 description 1
- 125000003836 4-phenylbutoxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 235000019753 Finisher Diet Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- BPZSYCZIITTYBL-YJYMSZOUSA-N R-Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000004896 Sulfotransferases Human genes 0.000 description 1
- 108090001033 Sulfotransferases Proteins 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 229960004620 bitolterol Drugs 0.000 description 1
- FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- JBRBWHCVRGURBA-UHFFFAOYSA-N broxaterol Chemical compound CC(C)(C)NCC(O)C1=CC(Br)=NO1 JBRBWHCVRGURBA-UHFFFAOYSA-N 0.000 description 1
- 229950008847 broxaterol Drugs 0.000 description 1
- 229960001386 carbuterol Drugs 0.000 description 1
- KEMXXQOFIRIICG-UHFFFAOYSA-N carbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(NC(N)=O)=C1 KEMXXQOFIRIICG-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229950010971 cimaterol Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229960004698 dichlorobenzyl alcohol Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229950002751 etanterol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 239000006056 finisher diet Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229960000708 hexoprenaline Drugs 0.000 description 1
- OXLZNBCNGJWPRV-UHFFFAOYSA-N hexoprenaline Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNCCCCCCNCC(O)C1=CC=C(O)C(O)=C1 OXLZNBCNGJWPRV-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 229950001479 imoxiterol Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229950004407 mabuterol Drugs 0.000 description 1
- JSJCTEKTBOKRST-UHFFFAOYSA-N mabuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(C(F)(F)F)=C1 JSJCTEKTBOKRST-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 229950004618 picumeterol Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960000859 tulobuterol Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Detergent Compositions (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52437603P | 2003-11-20 | 2003-11-20 | |
| PCT/US2004/037966 WO2005051092A2 (en) | 2003-11-20 | 2004-11-12 | Method of decreasing fat deposits and body weight in mammals and birds |
| US10/987,665 US20050113456A1 (en) | 2003-11-20 | 2004-11-12 | Method of decreasing fat deposits and body weight in mammals and birds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007515402A true JP2007515402A (ja) | 2007-06-14 |
| JP2007515402A5 JP2007515402A5 (https=) | 2007-07-26 |
Family
ID=34595131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006541282A Pending JP2007515402A (ja) | 2003-11-20 | 2004-11-12 | 哺乳動物および鳥類の体脂肪および体重の減少方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20050113456A1 (https=) |
| EP (1) | EP1684593A4 (https=) |
| JP (1) | JP2007515402A (https=) |
| AU (1) | AU2004292416B2 (https=) |
| CA (1) | CA2545559A1 (https=) |
| NZ (1) | NZ547178A (https=) |
| WO (1) | WO2005051092A2 (https=) |
| ZA (1) | ZA200604077B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2615173C (en) | 2005-07-14 | 2012-01-03 | Lipothera, Inc. | Sustained release enhanced lipolytic formulation for regional adipose tissue treatment |
| US20070264313A1 (en) * | 2006-05-12 | 2007-11-15 | Musser Robert E | Methods and compositions relating to animal dietary acids |
| JP2010506941A (ja) * | 2006-10-17 | 2010-03-04 | リセラ，インク． | 甲状腺眼症の治療のための方法、組成物及び製剤 |
| WO2009073051A1 (en) * | 2007-12-03 | 2009-06-11 | Bridge Pharma, Inc. | Use of rr/sr-ractopamine |
| WO2010027259A1 (en) | 2008-09-02 | 2010-03-11 | N.V. Nutricia | Nutritional compositions with coated lipid globules |
| WO2010068086A1 (en) | 2008-12-11 | 2010-06-17 | N.V. Nutricia | Nutritional compositions with large lipid globule size |
| US9132084B2 (en) * | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
| GB2487868B (en) * | 2010-01-15 | 2014-12-10 | Neothetics Inc | Lyophilized cake formulations |
| WO2011115476A1 (en) | 2010-03-17 | 2011-09-22 | N.V. Nutricia | Infant nutrition for improving fatty acid composition of brain membranes later in life |
| UA111822C2 (uk) * | 2010-11-24 | 2016-06-24 | Общєство С Огранічєнной Отвєтствєнностью "Новамедіка" | Монотерапевтичий препарат селективного ліпофільного бета-агоніста тривалої дії і спосіб косметичного лікування ожиріння і контурного випинання |
| ES2693519T3 (es) | 2013-11-01 | 2018-12-12 | N.V. Nutricia | Composición lipídica para mejorar la composición corporal durante el crecimiento de recuperación |
| KR102273533B1 (ko) * | 2015-06-15 | 2021-07-06 | 삼성전자 주식회사 | 무선 통신 시스템에서 서비스 제공 방법 및 장치 |
| WO2017064304A1 (en) | 2015-10-15 | 2017-04-20 | N.V. Nutricia | Infant formula with special lipid architecture for promoting healthy growth |
| ES2987545T3 (es) | 2016-12-09 | 2024-11-15 | Nutricia Nv | Composición nutricional para su uso en la mejora del rendimiento cognitivo y/o la prevención del deterioro cognitivo |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04507091A (ja) * | 1989-07-07 | 1992-12-10 | ニコメッド ダーク エイ／エス | 体重減量医薬組成物 |
| US5399765A (en) * | 1994-05-23 | 1995-03-21 | Sepracor, Inc. | Enantioselective preparation of optically pure albuterol |
| US5545745A (en) * | 1994-05-23 | 1996-08-13 | Sepracor, Inc. | Enantioselective preparation of optically pure albuterol |
| WO1998048810A1 (en) * | 1997-04-30 | 1998-11-05 | Bridge Pharma, Inc. | Composition and methods using an eutomer |
| WO2002048090A1 (en) * | 2000-12-11 | 2002-06-20 | Cipla Limited | Process for preparing isomers of salbutamol |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0085514A3 (en) * | 1982-01-28 | 1984-02-29 | Beecham Group Plc | Compositions comprising a beta-antagonist and a beta-agonist, their preparation, and their use in treating obese humans and animals |
| GB8604134D0 (en) * | 1986-02-19 | 1986-03-26 | Glaxo Group Ltd | Veterinary preparations |
| IE60964B1 (en) * | 1986-12-11 | 1994-09-07 | Roussel Uclaf | Zootechnical compositions containing a beta-adrenergic |
| US5147869A (en) * | 1986-12-11 | 1992-09-15 | Roussel Uclaf | Zootechnical compositions |
| US5541188A (en) * | 1987-09-15 | 1996-07-30 | The Rowett Research Institute | Therapeutic applications of beta-adrenergic agonists |
| US5530029A (en) * | 1987-09-15 | 1996-06-25 | The Rowett Research Institute | Therapeutic applications of clenbuterol |
| FR2642075B1 (fr) * | 1989-01-25 | 1991-04-26 | Pasteur Institut | Polypeptides ayant une activite de recepteur (beta)-adrenergique chez l'homme, impliques dans la reponse lipolytique, acides nucleiques codant pour ces polypeptides et utilisation de ces polypeptides pour le criblage de substance active sur ces polypeptides |
| JP3085705B2 (ja) * | 1990-01-05 | 2000-09-11 | セプラカー・インコーポレーテツド | 喘息の治療のための光学的純粋ｒ（−）アルブテロール |
| US5362755A (en) * | 1990-01-05 | 1994-11-08 | Sepracor, Inc. | Method for treating asthma using optically pure (R)-albuterol |
| JP3358631B2 (ja) * | 1993-05-17 | 2002-12-24 | 三菱瓦斯化学株式会社 | メタノ−ルの脱水素方法 |
| US5698199A (en) * | 1995-03-10 | 1997-12-16 | Kao Corporation | Lipolysis acceleration method |
| US5708036A (en) * | 1996-01-29 | 1998-01-13 | Pesterfield, Jr.; E. Charles | Method of treating premature uterine contractions using the optically active R(-)-isomer of albuterol |
| US7767708B2 (en) * | 1998-11-04 | 2010-08-03 | Schering-Plough Animal Health Corp. | Growth stimulant compositions |
| US6683115B2 (en) * | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
-
2004
- 2004-11-12 NZ NZ547178A patent/NZ547178A/en not_active IP Right Cessation
- 2004-11-12 WO PCT/US2004/037966 patent/WO2005051092A2/en not_active Ceased
- 2004-11-12 US US10/987,665 patent/US20050113456A1/en not_active Abandoned
- 2004-11-12 JP JP2006541282A patent/JP2007515402A/ja active Pending
- 2004-11-12 CA CA002545559A patent/CA2545559A1/en not_active Abandoned
- 2004-11-12 EP EP04810943A patent/EP1684593A4/en not_active Withdrawn
- 2004-11-12 AU AU2004292416A patent/AU2004292416B2/en not_active Ceased
-
2006
- 2006-05-19 ZA ZA2006/04077A patent/ZA200604077B/en unknown
-
2007
- 2007-08-06 US US11/834,580 patent/US20080020019A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04507091A (ja) * | 1989-07-07 | 1992-12-10 | ニコメッド ダーク エイ／エス | 体重減量医薬組成物 |
| US5399765A (en) * | 1994-05-23 | 1995-03-21 | Sepracor, Inc. | Enantioselective preparation of optically pure albuterol |
| US5545745A (en) * | 1994-05-23 | 1996-08-13 | Sepracor, Inc. | Enantioselective preparation of optically pure albuterol |
| WO1998048810A1 (en) * | 1997-04-30 | 1998-11-05 | Bridge Pharma, Inc. | Composition and methods using an eutomer |
| WO2002048090A1 (en) * | 2000-12-11 | 2002-06-20 | Cipla Limited | Process for preparing isomers of salbutamol |
Non-Patent Citations (5)
| Title |
|---|
| JPN6010013711, Ｗａｒｒｉｓｓ ＰＤ ｅｔ ａｌ．, "Ｔｈｅ ｅｆｆｅｃｔｓ ｏｆ ｔｈｅ ｂｅｔａ−ａｄｒｅｎｅｒｇｉｃ ａｇｏｎｉｓｔ ｓａｌｂｕｔａｍｏｌ ｏｎ ｍｅａｔ ｑｕａｌｉｔｙ ｉｎ ｐｉｇｓ", Ｊｏｕｒｎａｌ ｏｆ Ａｎｉｍａｌ Ｓｃｉｅｎｃｅ, 1990, ６８巻１号, ｐｐ．１２８−１３６ * |
| JPN6010013715, Ｓｏｔａ Ｅ ｅｔ ａｌ．, "Ｏｒｇａｎ ｗｅｉｇｈｔｓ， ｍｕｓｃｌｅ ｃｏｍｐｏｓｉｔｉｏｎ ａｎｄ ｆａｔｔｙ ａｃｉｄ ｐｒｏｆｉｌｅｓ ｉｎ ｌａｍｂｓ ｆｅｄ ｓａｌｂｕｔａｍｏｌ： Ｅｆｆｅｃｔ ｏｆ ａ ５−ｄａｙ", Ｍｅａｔ Ｓｃｉｅｎｃｅ, 1995, ４１巻１号, ｐｐ．２９−３５ * |
| JPN6010013722, Ｚｈａｎｇ ＸＹ ｅｔ ａｌ．, "Ｅｆｆｅｃｔｓ ｏｆ ｅｎａｎｔｉｏｍｅｒｓ ｏｆ ｂｅｔａ ２−ａｇｏｎｉｓｔｓ ｏｎ ＡＣｈ ｒｅｌｅａｓｅ ａｎｄ ｓｍｏｏｔｈ ｍｕｓｃｌｅ ｃｏｎｔｒａｃｔｉｏｎ ｉｎ ｔｈｅ ｔｒａｃｈｅ", Ａｍ Ｊ Ｐｈｙｓｉｏｌ Ｌｕｎｇ Ｃｅｌｌ Ｍｏｌ Ｐｈｙｓｉｏｌ, 1998, ２７４巻, ｐｐ．Ｌ３２−Ｌ３８ * |
| JPN6010013726, Ｂｏｕｌｔｏｎ ＤＷ ａｎｄ Ｆａｗｃｅｔｔ ＪＰ, "Ｔｈｅ ｐｈａｒｍａｃｏｋｉｎｅｔｉｃｓ ｏｆ ｌｅｖｏｓａｌｂｕｔａｍｏｌ ： Ｗｈａｔ ａｒｅ ｔｈｅ ｃｌｉｎｉｃａｌ ｉｍｐｌｉｃａｔｉｏｎｓ？", Ｃｌｉｎｉｃａｌ ｐｈａｒｍａｃｏｋｉｎｅｔｉｃｓ, 2001, ４０巻１号, ｐｐ．２３−４０ * |
| JPN7010000771, Ｍｉｒｋｉｎ Ｇ, "Ａｌｂｕｔｅｒｏｌ ｆｏｒ ｗｅｉｇｈｔ ｃｏｎｔｒｏｌ", Ｄｒ． Ｍｉｒｋｉｎ’ｓ ｆｒｅｅ ｗｅｅｋｌｙ Ｆｉｔｎｅｓｓ ａｎｄ Ｈｅａｌｔｈ ｅ−Ｚｉｎｅ, 199407, ｐａｇｅ １ * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20050113456A1 (en) | 2005-05-26 |
| ZA200604077B (en) | 2009-11-29 |
| EP1684593A4 (en) | 2010-02-10 |
| EP1684593A2 (en) | 2006-08-02 |
| WO2005051092A3 (en) | 2006-04-06 |
| CA2545559A1 (en) | 2005-06-09 |
| WO2005051092A2 (en) | 2005-06-09 |
| AU2004292416A1 (en) | 2005-06-09 |
| NZ547178A (en) | 2008-06-30 |
| AU2004292416B2 (en) | 2010-01-28 |
| US20080020019A1 (en) | 2008-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080020019A1 (en) | Method of decreasing fat deposits and body weight in mammals and birds | |
| AU2008331928B2 (en) | Use of RR/SR-ractopamine | |
| US8445542B2 (en) | Methods of accelerating muscle growth, decreasing fat deposits and improving feed efficiency in livestock animals | |
| Zahl et al. | Anesthesia induces stress in Atlantic salmon (Salmo salar), Atlantic cod (Gadus morhua) and Atlantic halibut (Hippoglossus hippoglossus) | |
| EP0732101B1 (en) | Use of L-deprenyl for retarding age dependent deterioration of the immune system function in mammals | |
| AU737608B2 (en) | Composition and methods using an eutomer | |
| JP2007515402A5 (https=) | ||
| JPH03500243A (ja) | ２‐デオキシ‐ｄ‐ヘキソースの経口投与による産肉性動物の飼料要求率の改良方法 | |
| JP6209208B2 (ja) | ブロイラー鶏の性能向上法 | |
| US20080070990A1 (en) | Use of ractopamine enantiomers | |
| CN109068685B (zh) | 含有日香木苷和/或夜香树苷的动物饲料添加剂 | |
| EP1787529A2 (en) | Composition and methods using an eutomer | |
| MXPA99009783A (en) | Composition and methods using an eutomer | |
| CN1882320A (zh) | 减少哺乳动物和鸟类的脂肪堆积物和体重的方法 | |
| McCartor | Tranquilizers or tranquilizing type compounds in beef cattle wintering and fattening rations | |
| WO2009020620A1 (en) | Synergisms between repartitioning and immunomodulating compounds | |
| THEJOMOORTHY | STUDIES ON THE EFFECT OF CERTAIN GROWTH PROMOTING AGENTS IN RABBITS FOR MEAT AND WOOLf HAIR PRODUCTION | |
| Lacy | Food intake regulation and tonic immobility in the domestic fowl as medicated by tyrosine and tryptophan | |
| HK1011611B (en) | Use of l-deprenyl for retarding age dependent deterioration of the immune system function in mammals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060726 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070427 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20080219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080219 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080219 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100319 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100906 |